All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On May 26, 2020, CLR 131, a radiotherapeutic phospholipid drug conjugate, was granted fast track designation by the U.S. Food and Drug Administration for the treatment of patients with lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia (LPL/WM) who received ≥ 2 prior treatment regimens.1
The fast track designation was based on the ongoing phase II CLOVER-1 trial (NCT02952508) which is evaluating CLR 131 in patients with relapsed/refractory B-cell malignancies, including LPL/WM and multiple myeloma.1 The dose-exploration portion of the study, Part A, demonstrated 100% overall response rates in patients with LPL/WM at 50 mCi (n = 2) and 75 mCi (n = 2) total body doses.2 The expansion cohort portion of the study, Part B, evaluating 100 mCi total body dose of CLR 131, showed that all patients (n = 4) with LPL/WM achieved 100% of overall response rate. One patient achieved a complete response rate,1 which is continuing for approximately 27 months.2
CLR 131 was previously granted Orphan Drug designation in LPL, and a fast track designation for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox